Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lineage Cell Therapeutics Inc

0.5200
+0.0000
Post-market: 0.52000.00000.00%19:51 EDT
Volume:875.50K
Turnover:461.14K
Market Cap:118.75M
PE:-5.59
High:0.5478
Open:0.5201
Low:0.5160
Close:0.5200
Loading ...

Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
14 Mar

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating

MT Newswires Live
·
14 Mar

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies

TIPRANKS
·
12 Mar

Q4 2024 Lineage Cell Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
11 Mar

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Mar

Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
11 Mar

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
11 Mar

Lineage Cell Therapeutics Inc - Q4 Revenue Around $2.9 Million

THOMSON REUTERS
·
11 Mar

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Business Wire
·
11 Mar

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
06 Mar

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Business Wire
·
05 Mar

Lineage Cell Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Feb

Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury

MT Newswires Live
·
11 Feb

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Feb

BRIEF-Lineage Initiates Clinical Study Of OPC1 For Spinal Cord Injury

Reuters
·
11 Feb

Lineage Initiates Clinical Study of Opc1 for Spinal Cord Injury

THOMSON REUTERS
·
11 Feb